Cargando…
Development of diabetes mellitus associated with quetiapine: A case series
We aimed to describe the characteristics and clinical course of patients who developed diabetes associated with the use of quetiapine. This study included patients who received quetiapine for over a month between April 2008 and November 2013, and were diagnosed as having new-onset diabetes after ini...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279094/ https://www.ncbi.nlm.nih.gov/pubmed/28099349 http://dx.doi.org/10.1097/MD.0000000000005900 |
_version_ | 1782502714632044544 |
---|---|
author | Nanasawa, Hideki Sako, Akahito Mitsutsuka, Tomohiko Nonogaki, Kaori Kondo, Tadayuki Mishima, Shuichi Uju, Yoriyasu Ito, Toshihiko Enomoto, Tetsuro Hayakawa, Tatsuro Yanai, Hidekatsu |
author_facet | Nanasawa, Hideki Sako, Akahito Mitsutsuka, Tomohiko Nonogaki, Kaori Kondo, Tadayuki Mishima, Shuichi Uju, Yoriyasu Ito, Toshihiko Enomoto, Tetsuro Hayakawa, Tatsuro Yanai, Hidekatsu |
author_sort | Nanasawa, Hideki |
collection | PubMed |
description | We aimed to describe the characteristics and clinical course of patients who developed diabetes associated with the use of quetiapine. This study included patients who received quetiapine for over a month between April 2008 and November 2013, and were diagnosed as having new-onset diabetes after initiation of quetiapine. We excluded patients who developed diabetes more than 1 year after discontinuation of quetiapine. We identified new-onset diabetes by hemoglobin A1c or prescriptions of antidiabetic drugs. Among 1688 patients who received quetiapine, hemoglobin A1c had been measured in 595 (35.2%) patients at least once during the observation period, and 33 (2.0%) patients had received hypoglycemic drugs. Eighteen (1.1%) patients were considered to have developed new-onset diabetes associated with quetiapine after a median of 1.6 years following initiation of quetiapine. Median (interquartile range) age was 54.5 (29.8) years, 8 patients were male, and median (interquartile range) duration of mental illness was 15.3 (13.8) years. Median hemoglobin A1c and body mass index (BMI) were 7.1 (1.4) % and 28.4 (7.0) kg/m(2), respectively. Seventeen patients had dyslipidemia when diabetes was discovered. All of these discontinued quetiapine within 3 months after the diagnosis of diabetes, and the diabetes in 4 patients had ameliorated without hypoglycemic drugs. Of 13 patients who had received either oral hypoglycemic drugs or insulin, 2 patients achieved well-controlled hemoglobin A1c without hypoglycemic drugs, and 10 patients had hemoglobin A1c 5.0% to 7.7% with the continued use of hypoglycemic drugs. We demonstrated that almost all patients who developed quetiapine-associated diabetes had dyslipidemia and increased BMI. There was no life-threatening hyperglycemia and diabetes was ameliorated just by discontinuation of quetiapine in several patients. The monitoring of metabolic parameters during antipsychotic treatment is important to diagnose and treat diabetes earlier. |
format | Online Article Text |
id | pubmed-5279094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-52790942017-02-08 Development of diabetes mellitus associated with quetiapine: A case series Nanasawa, Hideki Sako, Akahito Mitsutsuka, Tomohiko Nonogaki, Kaori Kondo, Tadayuki Mishima, Shuichi Uju, Yoriyasu Ito, Toshihiko Enomoto, Tetsuro Hayakawa, Tatsuro Yanai, Hidekatsu Medicine (Baltimore) 5000 We aimed to describe the characteristics and clinical course of patients who developed diabetes associated with the use of quetiapine. This study included patients who received quetiapine for over a month between April 2008 and November 2013, and were diagnosed as having new-onset diabetes after initiation of quetiapine. We excluded patients who developed diabetes more than 1 year after discontinuation of quetiapine. We identified new-onset diabetes by hemoglobin A1c or prescriptions of antidiabetic drugs. Among 1688 patients who received quetiapine, hemoglobin A1c had been measured in 595 (35.2%) patients at least once during the observation period, and 33 (2.0%) patients had received hypoglycemic drugs. Eighteen (1.1%) patients were considered to have developed new-onset diabetes associated with quetiapine after a median of 1.6 years following initiation of quetiapine. Median (interquartile range) age was 54.5 (29.8) years, 8 patients were male, and median (interquartile range) duration of mental illness was 15.3 (13.8) years. Median hemoglobin A1c and body mass index (BMI) were 7.1 (1.4) % and 28.4 (7.0) kg/m(2), respectively. Seventeen patients had dyslipidemia when diabetes was discovered. All of these discontinued quetiapine within 3 months after the diagnosis of diabetes, and the diabetes in 4 patients had ameliorated without hypoglycemic drugs. Of 13 patients who had received either oral hypoglycemic drugs or insulin, 2 patients achieved well-controlled hemoglobin A1c without hypoglycemic drugs, and 10 patients had hemoglobin A1c 5.0% to 7.7% with the continued use of hypoglycemic drugs. We demonstrated that almost all patients who developed quetiapine-associated diabetes had dyslipidemia and increased BMI. There was no life-threatening hyperglycemia and diabetes was ameliorated just by discontinuation of quetiapine in several patients. The monitoring of metabolic parameters during antipsychotic treatment is important to diagnose and treat diabetes earlier. Wolters Kluwer Health 2017-01-20 /pmc/articles/PMC5279094/ /pubmed/28099349 http://dx.doi.org/10.1097/MD.0000000000005900 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5000 Nanasawa, Hideki Sako, Akahito Mitsutsuka, Tomohiko Nonogaki, Kaori Kondo, Tadayuki Mishima, Shuichi Uju, Yoriyasu Ito, Toshihiko Enomoto, Tetsuro Hayakawa, Tatsuro Yanai, Hidekatsu Development of diabetes mellitus associated with quetiapine: A case series |
title | Development of diabetes mellitus associated with quetiapine: A case series |
title_full | Development of diabetes mellitus associated with quetiapine: A case series |
title_fullStr | Development of diabetes mellitus associated with quetiapine: A case series |
title_full_unstemmed | Development of diabetes mellitus associated with quetiapine: A case series |
title_short | Development of diabetes mellitus associated with quetiapine: A case series |
title_sort | development of diabetes mellitus associated with quetiapine: a case series |
topic | 5000 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279094/ https://www.ncbi.nlm.nih.gov/pubmed/28099349 http://dx.doi.org/10.1097/MD.0000000000005900 |
work_keys_str_mv | AT nanasawahideki developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT sakoakahito developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT mitsutsukatomohiko developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT nonogakikaori developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT kondotadayuki developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT mishimashuichi developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT ujuyoriyasu developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT itotoshihiko developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT enomototetsuro developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT hayakawatatsuro developmentofdiabetesmellitusassociatedwithquetiapineacaseseries AT yanaihidekatsu developmentofdiabetesmellitusassociatedwithquetiapineacaseseries |